News & Updates

Patients with type 2 diabetes (T2D) who received canagliflozin benefit from improved liver biochemistry and metabolism, a recent study has shown. In addition, treatment with canagliflozin appears to confer positive effects on liver fibrosis.

Higher consumption of both unprocessed and processed red meat is associated with higher risks of cardiovascular disease (CVD) and type 2 diabetes mellitus (T2DM), according to a meta-analysis involving >4.4 million people by researchers from the University of Hong Kong (HKU).

A population-based study suggests that the incidence of periodontitis co-occurs with various other diabetes-related complications, underpinning the importance of oral health checks in diabetes management.

In the treatment of patients with psoriasis, the phosphodiesterase (PDE)-4 inhibitor roflumilast has been found to also induce weight loss.

A new diagnosis of type 2 diabetes (T2D) raises the risk of cardiovascular disease (CVD) development within 10 years in both men and women and across age groups, particularly among younger patients, reveals a recent study.

Among type 2 diabetes (T2D) patients with and without comorbid cardiovascular disease, those who have been newly initiated to glucagon-like peptide-1 receptor agonists (GLP-1RA) or sodium-glucose cotransporter 2 inhibitors (SGLT2i) appear to enjoy greater reductions in the risks of stroke and death when compared with new users of dipeptidyl peptidase-4 inhibitors (DPP-4i), suggests a study.